

**Supplementary Figure 8 Ad-miR-151 treatment inhibited T<sub>H</sub>2 cell differentiation in** *Tskl***<sup>+</sup> mice. (A) qPCR analysis showing the serum levels of miR-151-5p in WT, Ad-GFP, and Ad-miR151-treated** *Tskl***<sup>+</sup> mice (n=6 per group). (B) Flow cytometric analysis showing the levels of T<sub>H</sub>2 cells in peripheral blood of WT, Ad-GFP, and Ad-miR-151-treated** *Tskl***<sup>+</sup> mice. (C) ELISA showing the levels of serum IL4 in WT, Ad-GFP, and Ad-miR-151-treated** *Tskl***<sup>+</sup> mice. (D) qPCR analysis showing the levels of miR-151-5p in WT, Ad-GFP, and Ad-miR-151-treated** *Tskl***<sup>+</sup> CD4 T cells cultured under the T<sub>H</sub>0 and T<sub>H</sub>2 conditions. (E) qPCR analysis showeing the expression levels of** *II***4 and** *Gata3* **in WT, Ad-GFP, and Ad-miR-151-treated** *Tskl***<sup>+</sup> CD4 T cells cultured under the T<sub>H</sub>0 and T<sub>H</sub>2 conditions. (F) ELISA showing IL4 production in the culture supernatant of WT, Ad-GFP, and Ad-miR-151-treated** *Tskl***<sup>+</sup> CD4 T cells under the T<sub>H</sub>0 and T<sub>H</sub>2 conditions. (G) Flow cytometric analysis showing T<sub>H</sub>2 cell percentage in WT, Ad-GFP, and Ad-miR-151-treated CD4 T cells under the T<sub>H</sub>0 and T<sub>H</sub>2 conditions. All experimental data were verified in at least 3 independent experiments. Error bars represent the s.d. from the mean values. \*\*\****P* **< 0.005; \*\****P* **< 0.01.**